BRIEF published on 06/06/2024 at 13:05, 1 year 5 months ago Theralase détruit avec succès le cancer du poumon Technologies Théralase Cancer Du Poumon Rutherrin® Étude Préclinique
PRESS RELEASE published on 06/06/2024 at 13:00, 1 year 5 months ago Theralase(R) Successfully Destroys Lung Cancer Theralase® Technologies Inc. announces preclinical success with Rutherrin® compound in targeting Non-Small Cell Lung Cancer. Results show improved tumour destruction and slower progression Theralase Technologies Inc. Cancer Treatment Preclinical Study NSCLC Rutherrin Compound
BRIEF published on 06/04/2024 at 13:05, 1 year 6 months ago Theralase® Technology Effective in Virus Inactivation Theralase Ruvidar Antiviral Research Virus Inactivation Heliyon
BRIEF published on 06/04/2024 at 13:05, 1 year 6 months ago Technologie Theralase® efficace pour l'inactivation des virus Theralase Ruvidar Recherche Antivirale Heliyon Inactivation Des Virus
PRESS RELEASE published on 06/04/2024 at 13:00, 1 year 6 months ago Theralase(R) Technology Effective in Virus Inactivation Theralase Technologies Inc. announces successful inactivation of various viruses with lead compound RuvidarTM through peer-reviewed research. Potential for viral vaccine development highlighted Theralase Technologies Inc. RuvidarTM Peer-Reviewed Research Viral Inactivation Viral Vaccine Development
BRIEF published on 05/30/2024 at 13:05, 1 year 6 months ago Theralase Releases 1Q2024 Financial Statements Financial Results Cancer Treatment Theralase Study II PDCs
BRIEF published on 05/30/2024 at 13:05, 1 year 6 months ago Theralase publie ses états financiers du 1T2024 Résultats Financiers Traitement Du Cancer Theralase Étude II PDC
PRESS RELEASE published on 05/30/2024 at 13:00, 1 year 6 months ago Theralase(R) Release's 1Q2024 Financial Statements Theralase® releases unaudited interim consolidated 1Q2024 financial statements. Company to host conference call on June 6th, 2024. Study II update and Break Through Designation progress discussed Conference Call Financial Statements Break Through Designation Theralase Study II
BRIEF published on 04/24/2024 at 13:05, 1 year 7 months ago Theralase Technologies Inc. Completes $750,200 Funding Round Private Placement Pharmaceuticals Clinical Research Investment Theralase Technologies
BRIEF published on 04/24/2024 at 13:05, 1 year 7 months ago Theralase Technologies Inc. finalise une ronde de financement de 750 200 $ Investissement Placement Privé Médicaments Recherche Clinique Technologies Théralase
Published on 12/05/2025 at 20:25, 45 minutes ago The Feedback Loop: Why SMX's Adoption in One Industry Accelerates Interest in All the Others
Published on 12/05/2025 at 20:15, 55 minutes ago When Proof Becomes Infrastructure, Markets Rewrite the Story (NASDAQ: SMX)
Published on 12/05/2025 at 19:50, 1 hour 20 minutes ago Gold, Rare Earth Minerals, Digital Assets: The Market Just Realized SMX Sits in All Three
Published on 12/05/2025 at 19:20, 1 hour 50 minutes ago The Multi-Sector Validation Shock: Why SMX Became Impossible for Markets to Ignore
Published on 12/05/2025 at 18:45, 2 hours 25 minutes ago Four Global Markets, One Engine: SMX Just Redefined What a Supply Chain Can Prove
Published on 12/05/2025 at 18:58, 2 hours 11 minutes ago EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Reduced earnings in Q3 2025/26 – Guidance for adjusted EBIT at previous year’s level still valid
Published on 12/05/2025 at 18:15, 2 hours 54 minutes ago Completion of merger to form Helvetia Baloise Holding Ltd
Published on 12/05/2025 at 17:46, 3 hours 23 minutes ago Booster Precision Components Holding GmbH announces the successful completion of its Written Procedure to amend and waive certain terms under the terms and conditions of the Bonds
Published on 12/05/2025 at 17:18, 3 hours 52 minutes ago La vidéo de la réunion de présentation des résultats 2024-2025 du 5 décembre 2025 est disponible
Published on 12/05/2025 at 17:18, 3 hours 52 minutes ago The video of the 2024-2025 results presentation meeting on December 5, 2025, is available
Published on 12/05/2025 at 15:10, 5 hours 59 minutes ago Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 15:10, 5 hours 59 minutes ago Mersen : nombre d'actions et de droits de vote au 30 novembre 2025
Published on 12/05/2025 at 13:58, 7 hours 11 minutes ago RELATIF A LA MISE A DISPOSITION DU PUBLIC DE LA NOTE D'INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LEGRAND FRANCE
